SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 25, 2018--
Veracyte,
Inc. (Nasdaq: VCYT) announced today that it has been awarded a 2018
Top Workplaces honor by the Bay Area News Group. This marks the fifth
consecutive year that Veracyte has received this prestigious award,
which is based solely on the results of an annual survey of Bay
Area-company employees.
“Receiving this honor for the fifth time validates the great culture our
team has created at Veracyte,” said Bonnie Anderson, Veracyte’s chairman
and chief executive officer. “We work very hard to ensure every one of
our employees understands our mission to improve patient care and their
absolute importance in helping us achieve it. This prestigious award is
a reflection of this daily effort, as well as the pride our employees
take in our company and the work we do.”
The Top Workplaces award winners are determined by results of an
employee feedback survey administered by WorkplaceDynamics, LLC, a
leading research firm that specializes in organizational health and
workplace improvement. Several key aspects of workplace culture were
measured for the award, including organizational alignment, effective
execution and meaningful connection with employees.
The Bay Area News Group published the complete list of 2018 Top
Workplaces on Sunday, June 24. The list of winners is available at the Bay
Area News Group website.
Veracyte’s corporate and industry leadership has been recognized
consistently over the past several years. In 2017, Ms. Anderson received
the 2017 Wallace H. Coulter Award for Healthcare Innovation from the
Biomedical Engineering Society and was named one of the “Fiercest Women
in Life Sciences” by FierceBiotech. In 2016, the company received the
prestigious Edison Award honoring excellence in new product and service
development, marketing, human-centered design and innovation.
About Veracyte
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics company
that is providing trustworthy and actionable answers that fundamentally
improve patient care when current diagnostic tests are uncertain. The
company's products uniquely combine genomic technology, clinical science
and machine learning to provide answers that give physicians and
patients a clear path forward without risky, costly surgery that is
often unnecessary. Since its founding in 2008, Veracyte has
commercialized three genomic tests, which are transforming the diagnosis
of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and
collectively target a $2 billion market opportunity. Veracyte is based
in South San Francisco, California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005125/en/
Source: Veracyte, Inc.
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Keith
Kennedy, 650-243-6357
Chief Financial Officer
keith@veracyte.com